ZURICH, July 20 – The following are some of the main factors expected to affect Swiss stocks on Tuesday:
Europe’s largest biotech confirmed its 2010 outlook after stronger-than-expected sales of its key heart and lung drug Tracleer, although quarterly profit lagged forecasts.
For related new click on [ATLN.VX]
BARRY CALLEBAUT (BARN.S)
The SIX Swiss Exchange Sanction Commission said differing expert opinions on accounting meant no sanction against Barry Callebaut.
For related news, click on [BARN.S]
* June trade data expected at 0615 GMT CHTBAL=ECI
COMPANY STATEMENTS [CNR-CH]
* Uster (USTN.S) posted H1 Positive net result of 4.0 million Swiss francs.
* Partners Group (PGHN.S) has been awarded a mandate by the sovereign wealth fund Korea Investment Corporation to invest in a broad range of opportunities in the private real estate market.
* Gottex (GFMN.S) said total fee earning assets for the group were 7.3 billion dollars compared to 7.9 billion dollars at 31 March 2010 largely driven by a 0.4 billion dollar negative impact from foreign exchange movements, performance and the return of cash to investors in run-off share classes.
* Partners Group, the global private markets investment manager, has been awarded a mandate by the sovereign wealth fund Korea Investment Corporation (KIC) to invest in a broad range of opportunities in the private real estate market.
* Baloise (BALN.VX) said it has acquired the Belgian insurance business of Avéro, a subsidiary of the Dutch Eureko Group. The purchase price amounts to 75 million euros. The purchase is expected to be completed by the second half of 2010.
* Novartis (NOVN.VX) said it had received approval in China for Rasilez, a first-in-class direct renin inhibitor for high blood pressure, the leading preventable cause of death in China.
EQUITY RESEARCH [CH-RCH]
FOR COMPANIES TRADING EX-DIVIDEND, PLEASE CLICK ON:
.EX.S for all Swiss stocks
.EXSMI.S for blue chips
.EXNSMI.S for other stocks